1. Introduction {#sec1}
===============

The gut microbiota of preterm infants is usually described as aberrant when compared to that of healthy term infants. Very often, the former is characterized by a notably lower bacterial diversity, a lower presence of bifidobacteria, and a higher concentration of potentially pathogenic bacteria \[[@B1]--[@B7]\]. This may have short-, medium-, and long-term health consequences since early colonizing organisms interact with the intestinal mucosa to shape the developing immune system \[[@B8], [@B9]\].

In fact, interactions with different components of the microbiota are crucial to the establishment and development of T-cell subsets, including NK, Treg, and Th17 cells, in the appropriate proportions to achieve homeostasis \[[@B10]\].

Many preterm infants lack an important part of transplacental transfer of maternal antibodies since this process occurs mainly in the last third of pregnancy; in addition, they have an impaired pattern-recognition receptor function and a reduced leukocyte endothelial adhesion and extracellular bacterial elimination \[[@B11]\]. Together, these alterations in the microbial colonization pattern and in the maturation of immune system, together with their stay in a hospital environment and other factors, predispose preterm infants to infections and/or to diseases such as necrotizing enterocolitis (NEC) \[[@B12]--[@B15]\].

The administration of probiotics to preterm neonates often leads to a decrease in the morbidity and mortality rates, in those of NEC and, in some cases, even in those of sepsis \[[@B16]--[@B22]\]. Additional benefits associated with probiotic supplementation in preterm neonates include earlier achievement of full enteral feeding \[[@B22]\], a lower colonization by*Enterobacteriaceae* \[[@B23]\], and a better neurological and immunological evolution \[[@B22], [@B24]\]. For these reasons, the number of institutions including probiotic supplementation in routine preterm care is increasing rapidly although the safety of probiotics in very low and extremely low birth weight infants is still a matter of debate \[[@B25]\], the mechanisms backing such effects are not well known yet \[[@B10]\], and global conclusions are difficult to establish because different studies usually make use of different probiotic strains, dosages, and/or treatment period.

Human milk is acknowledged as the best feeding option to preterm infants \[[@B26], [@B27]\] because its use decreases the incidence of many negative outcomes of prematurity, such as late onset sepsis or NEC \[[@B28]--[@B30]\]. In addition, human milk seems to be an important source of potentially beneficial bacteria to the infant gut and some strains may find future applications as probiotics for preterm infants \[[@B31]--[@B36]\]. In this context, the objective of this exploratory study was to assess early gut colonization in a short cohort of preterm neonates receiving a combination of two probiotic strains isolated from human milk. Furthermore, a wide variety of blood and fecal immunological parameters were assessed in order to elucidate their utility in future studies involving a larger cohort.

2. Materials and Methods {#sec2}
========================

2.1. Study Design and Sampling {#sec2.1}
------------------------------

Five preterm infants were enrolled in this study within 2 days after their birth. All of them met the following inclusion criteria: birth weight \< 1,300 g, gestational age at birth \< 29 weeks, and absence of any malformation or metabolic disease at birth. The most relevant demographic and clinical variables from mother-infant pairs were compiled by the Medical Staff of the Service of Neonatology of the Hospital Universitario La Paz (Madrid, Spain). The Ethical Committee on Clinical Research of the Hospital Universitario La Paz of Madrid approved all study protocols (code number: 3551). Samples and clinical information were obtained after written informed consent by the infants\' parents. This trial is registered with ClinicalTrials.gov identifier NCT02192996.

After spontaneous meconium expulsion (between the second and the fourth days of life), a mixture of*Bifidobacterium breve* PS12929 and*Lactobacillus salivarius* PS12934, containing \~1 × 10^9^ colony-forming units (CFU) of each strain, was suspended in a sterile saline solution and administered twice a day to the infants through an enteral feeding system. Meconium samples were collected prior to probiotic administration and, later, fecal (*n* = 14) and blood (*n* = 10) samples were collected weekly for up to 28 days. Fecal samples were aliquoted and stored at −80°C or −20°C until microbiological or immunological analysis, respectively. Blood samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes; subsequently, the plasma was obtained within 4 h after extraction and stored at −20°C until analysis.

2.2. Microbiological Analysis {#sec2.2}
-----------------------------

Adequate dilutions of five meconium and fourteen stool samples were spread onto Kanamycin Aesculin Azide Agar (KAA; Oxoid) for*Enterococcus* species isolation; de Man, Rogosa and Sharpe (MRS; Oxoid, Basingstoke, UK) supplemented with L-cysteine (0.5 g/L) (Sigma, St. Louis, USA) (MRScys) for isolation of lactic acid bacteria; MacConkey (MCK; BioMérieux, Marcy l\'Etoile, France) for isolation of*Enterobacteriaceae;* Sabouraud Dextrose Chloramphenicol (SDC, BioMérieux) for isolation of yeasts; TOS-Propionate (TOS; Merck, NJ, USA) for isolation of bifidobacteria; and Columbia Nalidixic Acid Agar (CNA, BioMérieux) as a general medium for isolation of other bacterial groups. Plates were aerobically incubated at 37°C for up to 48 h, with the exception of MRScys and TOS plates that were anaerobically incubated (85% nitrogen, 10% hydrogen, and 5% carbon dioxide) in an anaerobic workstation (Mini-MACS Don Whitley Scientific Limited, Shipley, UK) at 37°C for 48 h. Bacterial counts were recorded as the CFU/g of meconium or feces and transformed to log~10~ values before statistical analysis.

At least one representative of each different colony type obtained from each sample was isolated. Approximately 140 isolates were analyzed by optical microscopy and identified by MALDI-TOF mass spectrometry in a Vitek-MS instrument (BioMérieux, Marcy l\'Etoile, France) in the facilities of Probisearch S. L. (Tres Cantos, Spain).

Pulsed-field gel electrophoresis (PFGE) genotyping of all the isolates identified as*L. salivarius* or*B. breve* was carried following a protocol previously described \[[@B37]\]. The profiles were compared to those of*L. salivarius* PS12934 and*B. breve* PS12929, respectively.

2.3. Immunological Analysis {#sec2.3}
---------------------------

The concentration of 18 cytokines, chemokines, and growth factors, including interleukin (IL) IL-1~*β*~, IL-6, IL-12 (p70), interferon-*γ* (INF-*γ*), tumor necrosis factor-*α* (TNF-*α*), IL-2, IL-4, IL-10, IL-13, IL-17, IL-8, growth related oncogene-*α* (GRO-*α*), macrophage-monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1~*β*~ (MIP-1~*β*~), IL-5, IL-7, granulocyte colony stimulating factor (G-CSF), and granulocyte-macrophage colony stimulating factor (GM-CSF), was determined in 5 meconium, 14 feces, and 10 plasma samples by using a Bio-Plex 200 system instrument (Bio-Rad, Hercules, CA) and the Bio-Plex Pro Human Cytokine, Chemokine and Growth Factor Assays (Bio-Rad). Parallel, the concentration of immunoglobulin (Ig) IgG~1~, IgG~2~, IgG~3~, IgG~4~, IgM, and IgA was determined using the Bio-Plex Pro Human Isotyping Assay Kit (Bio-Rad).

Before analysis, 0.1 g of meconium and fecal samples was diluted in 0.9 mL of peptone water, homogenized, and centrifuged for 15 min at 14,000 ×g at 4°C; then, supernatants (≥200 *μ*L) were collected. Plasma samples were defrosted and properly diluted immediately before the immunological assay. Analyses were carried out in duplicate following the manufacturer\'s protocol and standard curves were performed for each analyte. Lower limit of quantification (LLOQ) was different for each one of the parameters, ranging from 0.02 to 11.74 ng/L for cytokines and from 0.01 to 2 ng/L for immunoglobulins.

Additionally, calprotectin levels (LLOQ: 8 ng/L) were determined in 5 meconium, 14 feces, and 8 plasma samples using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Calpro, Lysaker, Norway) according to the manufacturer\'s instructions. The standard curve of calprotectin was obtained from triplicates of each assayed concentration and fit to a 4-parameter curve model.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The statistical analysis was performed using R 2.15.3 (R-project, <http://www.r-project.org>). When data were not normally distributed, medians and interquartile ranges (Q1 and Q3) were calculated for all sampling times, and means and 95% confidence interval (95% CI) were used for normally distributed data. The richness and diversity of meconium and fecal microbiota were determined by calculating the Shannon-Weaver diversity index, which takes into account the number and evenness of the bacterial species. The Kruskal-Wallis test for nonnormal data or one-way ANOVA test, when data were normally distributed, was used to evaluate the differences between sampling times, in all measured variables, in plasma samples and for the comparison of immunological variables between plasma and fecal samples. The nonparametric Friedman test or one-way ANOVA test, when data were normally distributed, was used in fecal samples to evaluate the differences between sampling times in all measured variables. In all cases,*P* values of \<0.05 were considered to be significant. Redundancy analysis (RDA) was used for exploration of whole data sets and evaluation of the possible relationship between gut colonization and immunological parameters with the clinical status of the participants. Finally, heatmaps of plasma and fecal samples were plotted. To do this, calculation of Kendall\'s correlation coefficients was performed and Ward agglomeration methods were used to obtain the clustering of the variables and cases matrix.

3. Results {#sec3}
==========

3.1. Demographic and Clinical Characteristics of the Participants {#sec3.1}
-----------------------------------------------------------------

The clinical and demographic data of the mothers and infants who participate in this study are summarized in [Table 1](#tab1){ref-type="table"}. Although five preterm infants were included in this study, there were 2 sets of twins (infants 1 and 2; infants 3 and 4) and, therefore, data were collected from three mothers ([Table 1](#tab1){ref-type="table"}).

All the infants were female and were born by Cesarean section with a mean gestational age of 28 weeks and 2 days. The mean birth weight was 1,020.4 g and the mean height and head circumference were 34.5 cm and 25.0 cm, respectively. These parameters showed*Z*-scores \< 0. Infants stayed in the NICU a mean time of 30.6 days with a mean age at discharge of 65.4 days, which represented a mean corrected gestational age of 37 weeks and 5 days ([Table 1](#tab1){ref-type="table"}). Additional information of clinical features is provided as supplemental information (Supplemental Information 1; see Table S1 of the Supplementary Material available online at <http://dx.doi.org/10.1155/2015/538171>).

3.2. Microbiological Analysis {#sec3.2}
-----------------------------

Bacterial growth was detected in one meconium sample and in all the fecal samples. Differences in the bacterial counts of fecal samples were evaluated by nonparametric Friedman test on days 7, 14, 21, and 28 (data not shown).

Globally, the phylum*Firmicutes* predominated in all the fecal samples except in those belonging to infant 5 where*Proteobacteria* was present in a similar proportion ([Figure 1(a)](#fig1){ref-type="fig"}). On the other hand,*Proteobacteria* dominated at the 14th day of intervention in fecal samples of the siblings 3 and 4. The phylum*Actinobacteria*, mainly represented by the genus*Bifidobacterium*, was isolated from day 7 although not in all the fecal samples ([Figure 1(a)](#fig1){ref-type="fig"}).

Among the*Firmicutes*, the genera*Enterococcus* and*Lactobacillus* were isolated from all the fecal samples except in that of infant 2 at day 21 where*Lactobacillus* could not be detected. The bacterial counts of*Enterococcus* decreased significantly from day 7 to day 21 of treatment (*P* = 0.043) from 10.00 to 8.30 log CFU/g. In contrast,*Lactobacillus* counts increased from 6.60 log CFU/g after 7 days of probiotic treatment to 8.32 log CFU/g at the end of the intervention; in this case, the differences were not statistically significant due to both the individual variability and the small cohort. The genus*Staphylococcus* was mainly isolated in the first weeks of the study from meconium and 7-day fecal samples ([Figure 1(b)](#fig1){ref-type="fig"}) with median counts of 4.30 and 9.44 log CFU/g, respectively.

In relation to*Proteobacteria*, the genus*Enterobacter* was isolated from all the fecal samples except from two from infant 2 (days 7 and 21) and from one of infant 3 at day 28 ([Figure 1(b)](#fig1){ref-type="fig"}). Similarly, the genus*Klebsiella* was isolated from all fecal samples except from two collected at day 7 (siblings 3 and 4) and one at day 21 (infant 2). Bacterial counts of these two genera were significantly different at every sampling day (*P* = 0.007 and 0.046 for*Enterobacter* and*Klebsiella*, resp.) and a decrease was observed in*Klebsiella* median counts (from 10.19 log CFU/g at day 7 to 8.48 log CFU/g at day 28).

Finally, the*Bifidobacterium* median counts oscillated between 7.98 and 9.98 log CFU/g in the 6 fecal samples where this genus was detected ([Figure 1(b)](#fig1){ref-type="fig"}).

The SDI of the fecal samples fluctuated during the study probably due to the different antibiotic treatments that the infants received ([Figure 1(c)](#fig1){ref-type="fig"}).

In order to detect the presence of*L. salivarius* PS12934 and*B. breve* PS12929 in fecal samples, all the fecal isolates belonging to such species were PFGE genotyped. This technique revealed that*L. salivarius* PS12934 was present in all the infants at numerous sampling points while*B. breve* PS12929 could be detected after day 14.

The heatmap obtained from the fecal samples at different sampling times of all the infants is shown in Figure S1. The dendrogram resulted after Kendall correlation coefficient calculation highlights the similar species profile of fecal samples of infant 2 at different sampling times and the almost identical species profile of fecal samples from days 7 and 14 of twins 3 and 4.

3.3. Immunological Analysis {#sec3.3}
---------------------------

A wide range of immune compounds were analyzed in plasma and fecal samples of the preterm infants throughout the study. An exploratory screening, using a principal component analysis (PCA) to detect outliers, revealed that the 7th day fecal sample from infant 4 was very different from the rest of the sample sets (data not shown). This infant was suffering a gastric bleeding at this sampling time and, therefore, this sample was excluded from the results of data sets.

Median values of the immune compounds concentrations in meconium and, also, in fecal samples at 7th and 14th days of probiotic supplementation are shown in [Table 2](#tab2){ref-type="table"}. In general, the values obtained for all the immune factors showed a high interindividual variability in both detection frequencies and amounts. The levels of some immune compounds changed throughout the study; those of IgG~2~ and MCP-1 decreased progressively (*P* = 0.074 and *P* = 0.076, resp.) while that of IgA increased (\>50 times) from meconium to fecal samples obtained at day 7 after birth (*P* = 0.074) ([Table 2](#tab2){ref-type="table"}). However, only the inflammatory biomarker calprotectin decreased significantly along sampling time (*P* = 0.041).

Plasma concentrations of the immune compounds are shown in [Table 3](#tab3){ref-type="table"} and, as it can be observed, no significant changes were found. Globally, chemokines and proinflammatory compounds tended to decrease, with the exception of IL-12 and TNF-*α*. The levels of the latter and those of the anti-inflammatory compounds remained very constant along time. Plasma immunoglobulins also showed a high individual variability although all decreased, with the exception of IgG4 and IgM ([Table 3](#tab3){ref-type="table"}).

The plasma concentrations of the different immune compounds were compared with their respective fecal values. All the immunoglobulins, with the exception of IgA, were significantly different in both types of samples. Among the remaining immune parameters, calprotectin, IL-10, GRO-*α*, and GM-CSF were significantly higher in feces (*P* = 0.000, *P* = 0.045, *P* = 0.048, and *P* = 0.000, resp.) while IL-8, MCP-1, and MIP-1~*β*~ were more abundant in plasma (*P* = 0.012, *P* = 0.000, and *P* = 0.001, resp.) (Table S2).

3.4. Multivariate Analysis of the Studied Population {#sec3.4}
----------------------------------------------------

A multivariate analysis was performed for investigating the possible relationship between clinical features and the immunological and microbiological profiles of fecal and plasma samples. The clinical variables considered were the following: antibiotherapy (Antibiotics); air way resume (AWResume) including ventilation, caffeine, and surfactant treatment; C-RP; hemoglobin amounts (Hb); hematocrit percentage (Hcte); ibuprofen treatment (Ibu.T); ibuprofen doses (Ibu.doses); number of stools per day (N°.stools); nutrition resuming the median feeding type (Nutrition); patent ductus arteriosus (PDA); Sepsis; spontaneous stools (Spont.stools); Transfusion; and Weight.

The redundancy analysis (RDA) of the above-mentioned variables for fecal samples is shown in [Figure 2](#fig2){ref-type="fig"}. The obtained model explains the 33% of the variability and the ANOVA test of the model was statistically significant (*P* = 0.020). The meconium samples were located opposite to microbial growth and in coincidence with the constrained antibiotic vector. Although the rest of fecal samples showed a less clear separation, the evolution of microbial colonization can be observed along the RDA1 axis in coincidence with the constrained vectors for AWResume, Nutrition, Spont.stools, PDA, and Transfusion and in opposite not only with the antibiotics and C-RP vectors, but also with the coordinates of proinflammatory compounds, such as calprotectin, MCP-1, MIP-1~*β*~, TNF-*α*, and IL-8 ([Figure 2](#fig2){ref-type="fig"}).

The RDA of plasma samples ([Figure 3](#fig3){ref-type="fig"}) explains the 70% of the variability and the ANOVA test of the model was statistically significant (*P* = 0.010). The bidimensional plot shows two points clearly separated from the others: infant 4 at day 19 and infant 5 at day 7. Three different situations were observed; on the one hand coordinates from infants 1, 2, and 3 did not change among sampling times, while on the other infant 5 showed a normalization far away of proinflammatory variables and hematological parameters coordinates; and finally infant 4 that initially was close to her corresponding twin and the rest of participants appeared at day 19, in the positive RDA1 and RDA2 coordinates, related to constrained variables vectors corresponding to C-RP, Sepsis, and PDA reflecting the clinical worsening of this infant at this moment.

Those clinical categorical variables explained by the fecal and plasma RDAs were used, together with the microbiological, immunological, and clinical parameters, to create two heatmaps, one for each type of samples ([Figure 4](#fig4){ref-type="fig"}). The results from all the available fecal samples of the 5 infants were used to perform the heatmap showed in [Figure 4(a)](#fig4){ref-type="fig"}. The samples\' dendrogram shows two arms which clearly separate meconium and feces. The variables\' dendrogram, obtained after samples clustering, shows two principal arms. The lower one is divided into two: the first of them that included clinical variables, some bacterial genera such as*Escherichia*,*Staphylococcus*,*Bifidobacterium*, and*Paenibacillus,* immunoglobulins IgG~3~ and IgG~4~, and cytokines IL-4, IL-13, and IL-2 and the second one that included antibiotherapy, IgG~1~, IL-5, IL-6, and IL-7. The upper arm is also divided and included the rest of the bacterial genera and immunological parameters together with the weight of the infants. The results obtained for all the available plasma samples from the 5 participants were used to perform the heatmap showed in [Figure 4(b)](#fig4){ref-type="fig"}. The plasma samples\' dendrogram shows two groups, in one of them 2 samples of the infant 2 cluster together with her twin at day 14 and samples of infant 5 clusters together with sample of infant 1 at day 7. In the second arm, siblings 3 and 4 at day 14 of probiotic supplementation initiate the clustering, which ends with sample of day 7 of infant 5 and sample of day 19 of infant 4 as previously observed in [Figure 3](#fig3){ref-type="fig"}. The dendrogram related to variables, obtained after infants clustering, showed two principal arms: one of them included clinical variables, hematological parameters, calprotectin, IL-1~*β*~, IL-4, IL-13, immunoglobulins IgA and IgG~3~, ibuprofen doses, and Hb and the second principal arm also divided including most of the cytokines, chemokines, and growth factors, the rest of the immunoglobulins, the birth weight, and the Hcte.

4. Discussion {#sec4}
=============

In this pilot study, the bacterial composition of fecal samples obtained from five preterm infants supplemented with a probiotic mixture of two strains isolated from human milk during their earlier days of life at the NICU was assessed. In addition, a wide range of cytokines, chemokines, growth factors, and immunoglobulins were determined in all plasma, meconium, and fecal samples in order to describe their immunological profiles, their changes over time, and their potential relationship with bacterial colonization and clinical features.

The results obtained in this study suggest that the administration of*B. breve* PS12929 and*L. salivarius* PS12934 to preterm infants may increase the levels of*Lactobacillus* and*Bifidobacterium* in their feces. In fact,*L. salivarius* PS12934 could be isolated from the fecal samples of the preterm infants from day 7 of intervention and its presence remained constant throughout the study.*B. breve* PS12929 was also isolated from fecal samples after day 14 of intervention and, since then, it had increasing presence in the fecal samples. The higher frequency and concentration of*Lactobacillus* and*Bifidobacterium* in the feces analyzed should be considered a positive outcome of this study because the pattern of gut colonization in this specific infant population is usually characterized by a dominance of opportunistic pathogens and a reduced (or even absent) population of lactobacilli and bifidobacteria \[[@B7], [@B15], [@B38]\]. In fact, the SDI values of the fecal samples were higher than those previously described in a similar cohort that did not receive probiotics \[[@B7]\]. The intensive use of antibiotics at the NICU has been related to a dramatic reduction in microbial diversity and to increased presence of*Enterobacter* \[[@B39]\]; however, the administration of the probiotic strains in this study seemed to, somehow, compensate the antibiotic side effects.

Up to the present, there has been a complete lack of studies focused on fecal immunological parameters among preterm infants. As a consequence, there are no reference values for this population and, therefore, this study may constitute a starting point for future investigations. Although scarce, there are some studies dealing with blood immune compounds in preterm babies. Globally, they show that there are differences in the blood immune profiles depending on the infant gestational age \[[@B40]--[@B42]\]. It is important to note that the volume of the blood samples that are usually extracted from preterm neonates for clinical purposes is usually very low. Therefore, multiplex technologies, as the one used in this study, are required in order to be able to simultaneously analyze a high number of immune compounds \[[@B42], [@B43]\].

The results obtained in this study must be interpreted with caution due to three relevant limitations: the absence of a control group, a very small population size, and the scarcity of previous studies dealing with the immunological features of very low or extremely low weight birth infants and how they may be affected after a probiotic treatment. In this context, the levels of IL-8 found in a previous work focused on term neonates \[[@B44]\] were lower than those obtained in this study while those of IL-4 and IL-6 were similar; in contrast, the values of the remaining immunological parameters were higher in all the sampling times. This may illustrate the immune immaturity of these preterm infants. Similarly, levels of IL-2, IL-6, IL-8, IL-10, IL-13, IL-17, TNF-*α*, IFN-*γ*, and MCP-1 were lower in preterm infants born at 30--32 weeks than in those born after 36 weeks, indicating a lower stimulation or activation of Th1 cells and antigen-presenting cells in preterm babies as the gestational age decreases \[[@B42]\]. In the present work, the concentrations of the chemokines IL-8 and MCP-1 and those of the cytokines IL-4, IL-10, and IL-13, which are related to anti-inflammatory processes, were higher than those reported for preterm neonates born at 30--32 weeks and similar to those found in older infants (\>36 weeks) \[[@B42]\]. This suggests that the administration of the probiotic strains may exert a modulatory effect on the immune system of these infants.

In addition, very low or extremely low weight birth infants usually require a strong and highly individualized medical intervention (antibiotics, oxygen, corticoids, ibuprofen, transfusions, etc.) for, at least, the first days of life due to a wide variety of life-threatening conditions. Such conditions, together with their corresponding treatments, may alter the microbial gut colonization process and, also, the infants\' immune responses. Therefore, it is very difficult to obtain a homogeneous VLBW or ELBW infant population even in cohorts with a high number of infants. This is another important limitation that interventional studies, such as probiotic administration, must face when dealing with such infant subpopulations.

Despite all the limitations cited above, it is also true that a significant reduction of the inflammatory marker calprotectin in feces was observed throughout the probiotic treatment, which is in agreement with previous studies \[[@B3], [@B45], [@B46]\]. This is a promising outcome that must be reassessed in the future in a placebo-controlled intervention involving a large cohort.

The increase in IgA observed at day 7 may be due to the microorganisms colonizing the preterm gut, which triggers the production of this Ig by the gut-associated lymphoid tissue (GALT) \[[@B47]\]. IgA has the ability to penetrate the gut mucosal surface in conjunction with antigens and, as a consequence, to induce effector immune responses, playing a key role in the maintenance of intestinal microbiota and immune homeostasis \[[@B48]\].

The multivariate analysis applied to all the available plasma and fecal samples from the five preterm infants revealed a clear relation between the parameters assessed in this work and the clinical evolution of the infants. In the fecal-related RDA, microbial colonization acted as the principal agent opposed to the levels of certain proinflammatory immunocompounds and in agreement with the clinical variables associated with an improvement of the infants\' health. Since bacterial species coordinate coefficients had positive values in the RDA1 axis, calprotectin and other proinflammatory parameters, such as IL-8, MIP-1~*β*~, MCP-1, G-CSF, or TNF-*α*, showed negative values. RDA1 axis coordinate coefficients for IgG~1~, IgG~2~, and IgG~4~ were negative while those for the secretory IgA and IgM immunoglobulins were positive. Although these findings must be taken with caution due to the inherent limitations of this work and to the high number of potential interactions and confusing factors, it should be noted that an abnormal gut microbial colonization predisposes the neonatal intestine to inflammation and to a cascade of proinflammatory and anti-inflammatory cytokines responses \[[@B49]\]. On the other hand, the evolution of the infants\' microbiota was different than that observed in other preterm infants devoid of probiotic treatment \[[@B7]\] but similar to that of preterm neonates that received probiotics \[[@B23]\].

Finally, the dendrograms obtained for samples and variables represented in the heatmaps ([Figure 4](#fig4){ref-type="fig"}) seem to reinforce the hypothesis that probiotic strains may contribute to the development of a normal gut bacterial colonization and that this process is essential to reduce the health burden associated with prematurity \[[@B50], [@B51]\]. Although the present cohort was very small, a promising influence of the probiotic supplementation on gut colonization was observed, including an increase in bacterial diversity and in the presence of lactobacilli and bifidobacteria at relatively high levels.

Although multicenter, randomized clinical trials involving bigger cohorts and longer intervention times with these strains will be required to determine their efficacy in the prevention of sepsis or NEC, the results of this work may provide useful information for future studies dealing with probiotic gut colonization and, particularly, with the detection and quantification of fecal and blood immunocompounds in preterm infants.
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![Phyla (a), genera (b), and bacterial diversity assessment by the SDI (c) of the microbiota of the meconium and fecal samples analyzed in this study. The relative contributions of the phyla and genera to the microbiota of the infant\'s gut and the SDI values were labeled per case and sampling time.](JIR2015-538171.001){#fig1}

![Redundancy analysis of the fecal samples obtained at different sampling times from the preterm infants. Cases were represented with points and then labeled per infant (1: circle, 2: square, 3: diamond, 4: triangle, and 5: inverted triangle) and sampling time (0: medium violet red, 7: green, 14: midnight blue, and 21: sky blue) Quantitative variables matrix, including the hematological and immunological parameters, ibuprofen doses (Ibu.doses), number of stools per day (N°.stools), and weight, was represented with each variable name or abbreviator in dark red color; clinical categorized observations vectors matrixes were used as constrained variables (airway resume (AWResume), antibiotherapy (Antibiotics), C-RP, ibuprofen treatment (Ibu treatment), nutrition type (Nutrition), patent ductus arteriosus (PDA), Sepsis, spontaneous stools (Spont.stools), and Transfusion) and represented as vectors in green color. The bidimensional RDA plot explains the 33% of the variability and showed a *P* value of 0.020 after 299 permutations when ANOVA test of the model was performed.](JIR2015-538171.002){#fig2}

![Redundancy analysis of the blood samples obtained at different sampling times from the preterm infants. Cases were represented with points and then labeled per infant (1: circle, 2: square, 3: diamond, 4: triangle, and 5: inverted triangle) and sampling time (0: medium violet red, 7: green, 14: midnight blue, and 21: sky blue) Quantitative variables matrix, including the hematological and immunological parameters, ibuprofen doses (Ibu.doses), number of stools per day (N°.stools), and weight, was represented with each variable name or abbreviator in dark red color; clinical categorized observations vectors matrixes were used as constrained variables (airway resume (AWResume), antibiotherapy (Antibiotics), C-RP, ibuprofen treatment (Ibu treatment), nutrition type (Nutrition), patent ductus arteriosus (PDA), Sepsis, spontaneous stools (Spont.stools), and Transfusion) and represented as vectors in green color. The bidimensional RDA plot explains the 71% of the variability and showed a *P* value of 0.010 after 199 permutations when ANOVA test of the model was performed.](JIR2015-538171.003){#fig3}

![Heatmaps of fecal (a) and plasma (b) samples matrixes, considering all the quantitative variables measured and the categorized variables that were explained in the correspondent RDA, were performed. Clustering functions were applied to samples and variables after scaling the whole data set. In order to represent as much information as possible in the plot, the heatmaps were plotted using the measured data matrix scaled per variable and columns were labeled per infant and sampling time.](JIR2015-538171.004){#fig4}

###### 

Epidemiological and clinical relevant data from the mother-infant pairs of this study.

  Mothers                                       1              2            3                             
  --------------------------------------------- -------------- ------------ -------------- -------------- -------------
  Age (years)                                   30             18           28                            
  Fever                                         No             Yes          No                            
  Leukocytosis (\>15,000 leukocytes/*µ*L)       No             Yes          Yes                           
  C-reactive protein (mg/L)                     26             7.6          40                            
  Antenatal antibiotics treatment               Yes            Yes          Yes                           
  Antenatal corticosteroids treatment           Complete       Uncomplete   Complete                      
  Chorioamnionitis                              No             Yes          Yes                           
  Type of delivery                              C-section      C-section    C-section                     
  Multiple delivery                             Yes            Yes          No                            
                                                                                                          
  Infants                                       1              2            3              4              5
                                                                                                          
  Rupture of fetal membranes (h)                672            0            0              0              432
  Twin position                                 1              2            2              1              1
  Sex                                           F              F            F              F              F
  Gestational age (wk)                          28 + 5         28 + 5       28 + 6         28 + 6         27 + 2
  Birth weight (g) (*Z*-score)                  1070 (−0.71)   980 (1.01)   1082 (−0.66)   1200 (−0.26)   770 (−1.02)
  Birth height (cm) (*Z*-score)                 36 (−1.3)      36 (−1.3)    36 (−1.3)      36 (−1.3)      32 (−1.8)
  Birth head circumference (cm) (*Z*-score)     26 (−0.8)      26 (−0.8)    25.5 (−1.1)    26 (−0.8)      24 (−0.8)
  Apgar score at 1 min                          8              9            8              5              7
  Apgar score at 5 min                          9              9            9              7              8
  Revival                                       Ventilation    No           Ventilation    Ventilation    Ventilation
  PDA                                           Yes            No           Yes            Yes            No
  Meconium spontaneous expulsion                Yes            Yes          Yes            Yes            Yes
  Meconium expulsion (h)                        24             9            48             36             14
  Probiotic starting age (d)                    2              2            2              2              4
  Probiotic treatment length (d)                18             18           31             19             25
  NICU stay (d)                                 18             8            14             64             49
  Age at discharge (d)                          51             51           60             64             101
  Corrected gestational age at discharge (wk)   36             36           37             38             42
  Death                                         No             No           No             Yes            No

PDA: patent ductus arteriosus; NICU: neonatal intensive care unit.

Antenatal corticosteroid treatment was uncompleted or complete when mother received one or two doses of betamethasone, respectively, within one week and 24 h before delivery.

Apgar test ranged from 1 to 10: less than 5 means risk; up to 7 means normal.

Twin position means the position at birth, 1 being the infant who was nearest to the cervix.

###### 

Frequency and concentration of immune compounds in fecal samples (*N* = 14) along time.

                           Day 0 (*N* = 5)   Day 7 (*N* = 4)              Day 14 (*N* = 5)   *P* value^\*^                                                       
  ------------------------ ----------------- ---------------------------- ------------------ ---------------------------- --------- ---------------------------- -------
  Immunoglobulins                                                                                                                                                 
   IgG~1~                  5 (100)           3.95 (1.23--6.36)            4 (100)            0.45 (0.23--0.80)            5 (100)   1.26 (0.47--2.43)            0.819
   IgG~2~                  5 (100)           23.82 (23.19--24.17)         4 (100)            2.98 (2.46--3.97)            5 (100)   2.66 (2.60--3.62)            0.074
   IgG~3~                  4 (80)            0.02 (0.01--0.02)            1 (25)             0.01 (0.01--0.01)            2 (40)    0.22 (0.11--0.32)            0.424
   IgG~4~                  5 (100)           0.03 (0.02--0.14)            4 (100)            0.02 (0.01--0.03)            5 (100)   0.03 (0.00--0.06)            0.449
   IgM                     4 (80)            2.72 (0.19--8.73)            3 (75)             1.10 (0.87--6.00)            5 (100)   2.79 (0.44--10.02)           0.819
   IgA                     5 (100)           3.57 (0.88--21.73)           4 (100)            201.23 (35.09--356.74)       5 (100)   7.49 (2.96--7.78)            0.074
                                                                                                                                                                 
                                             (ng/kg)                                         (ng/kg)                                (ng/kg)                       
                                                                                                                                                                 
  Proinflammatory                                                                                                                                                 
   Calprotectin^†^         5 (100)           309.50 (282.00--343.90)      4 (100)            144.80 (132.30--180.40)      5 (100)   38.42 (34.16--63.96)         0.041
   IL-1~β~ ^‡^             1 (20)            31.47                        3 (75)             41.34 (8.00--74.68)          3 (60)    39.20 (−36.24--114.64)       0.937
   IL-2                    1 (20)            8.47                         1 (25)             8.18                         0 (0)     ---                          0.368
   IL-6                    0 (0)             ---                          0 (0)              ---                          1 (20)    27.44                        0.368
   IL-12 (p70)             2 (40)            29.07 (28.82--29.32)         2 (50)             37.13 (36.38--37.89)         1 (20)    82.98                        0.926
   IL-17                   2 (40)            72.94 (62.76--83.11)         2 (50)             66.08 (64.46--67.71)         2 (40)    69.31 (65.15--73.48)         1.000
   IFN-*γ*                 4 (80)            214.90 (190.40--238.30)      4 (100)            299.80 (255.40--320.80)      4 (80)    248.10 (215.80--265.50)      0.449
   TNF-*α*                 1 (20)            20.87                        0 (0)              ---                          0 (0)     ---                          0.368
                                                                                                                                                                 
                                             (ng/kg)                                         (ng/kg)                                (ng/kg)                       
                                                                                                                                                                 
  Anti-inflammatory                                                                                                                                               
   IL-4                    3 (60)            2.74 (2.43--3.48)            4 (100)            2.63 (2.49--2.85)            3 (60)    2.12 (2.06--2.26)            0.268
   IL-5                    0 (0)             ---                          0 (0)              ---                          0 (0)     ---                          ---
   IL-10                   1 (20)            25.62                        2 (50)             37.21 (35.85--38.57)         3 (60)    39.20 (38.66--53.87)         0.319
   IL-13                   0 (0)             ---                          0 (0)              ---                          0 (0)     ---                          ---
                                                                                                                                                                 
                                             (ng/kg)                                         (ng/kg)                                (ng/kg)                       
                                                                                                                                                                 
  Chemokines                                                                                                                                                      
   IL-8                    4 (80)            20.94 (19.00--23.82)         3 (75)             16.16 (15.56--17.20)         2 (40)    17.05 (16.45--17.64)         0.128
   GRO-*α* ^‡^             5 (100)           206.30 (117.04--295.57)      3 (75)             222.10 (−77.61--521.80)      4 (80)    263.50 (261.05--265.88)      0.763
   MCP-1                   5 (100)           20.08 (15.02--28.89)         2 (50)             18.37 (16.82--19.93)         3 (60)    16.98 (14.21--17.34)         0.076
   MIP-1~*β*~              5 (100)           53.79 (52.03--68.66)         4 (100)            58.16 (46.46--66.42)         4 (80)    49.60 (35.16--69.89)         0.449
                                                                                                                                                                 
                                             (ng/kg)                                         (ng/kg)                                (ng/kg)                       
                                                                                                                                                                 
  Haematopoietic stimuli                                                                                                                                          
   IL-7                    0 (0)             ---                          0 (0)              ---                          0 (0)     ---                          ---
   G-CSF                   1 (20)            28.99                        0 (0)              ---                          0 (0)     ---                          0.368
   GM-CSF                  5 (100)           1729.00 (1086.00--2312.00)   4 (100)            1830.00 (1648.00--2010.00)   4 (80)    1879.00 (1783.00--1920.00)   0.819

Levels of immune compounds were expressed as median and interquartile range (IQR) when data were not normally distributed and as mean and 95% confidence interval (95% CI) when they were. ^\*^Friedman test was used to determine the differences between fecal samples along time when data were not normally distributed and one-way ANOVA when they were. ^†^Concentration was expressed as ng/Kg of feces for all the proinflammatory parameters with the exception of calprotectin whose units were mg/Kg. ^‡^Normally distributed.

###### 

Frequency and concentration of immune compounds in plasma samples (*N* = 8) along time.

                           Day 7 (*N* = 3)   Day 14 (*N* = 5)             *P* value^\*^                                
  ------------------------ ----------------- ---------------------------- --------------- ---------------------------- -------
  Immunoglobulins                                                                                                       
   IgG~1~                  3 (100)           2159.80 (2075.95--2174.30)   5 (100)         1727.30 (1205.50--2029.60)   0.297
   IgG~2~                  3 (100)           1135.20 (796.03--1147.50)    5 (100)         741.24 (683.84--930.95)      0.456
   IgG~3~                  3 (100)           52.54 (46.75--64.53)         5 (100)         43.91 (41.35--48.14)         0.297
   IgG~4~                  3 (100)           23.25 (22.02--67.30)         5 (100)         44.66 (10.59--49.08)         0.655
   IgM                     3 (100)           263.75 (176.71--934.18)      5 (100)         335.18 (261.41--366.78)      0.882
   IgA                     3 (100)           27.03 (18.20--40.41)         5 (100)         4.44 (4.00--14.31)           0.101
                                                                                                                       
                                             (ng/L)                                       (ng/L)                        
                                                                                                                       
  Proinflammatory                                                                                                       
   Calprotectin^†^         3 (100)           0.86 (0.47--1.11)            5 (100)         0.37 (0.37--0.63)            0.456
   IL-1~β~ ^‡^             1 (33)            15.81                        0 (0)           ---                          ---
   IL-2                    2 (67)            35.41 (19.34--51.48)         3 (60)          9.70 (6.54--11.23)           1.000
   IL-6                    3 (100)           24.14 (15.99--65.65)         5 (100)         17.06 (10.10--19.24)         0.297
   IL-12 (p70)             3 (100)           27.55 (19.89--91.22)         5 (100)         28.35 (22.71--29.16)         0.882
   IL-17                   1 (33)            167.20                       2 (40)          35.66 (34.65--36.67)         0.221
   IFN-*γ*                 2 (67)            670.07 (371.30--968.83)      4 (80)          150.06 (67.73--225.91)       0.643
   TNF-*α*                 3 (100)           15.06 (11.35--66.01)         5 (100)         13.14 (11.83--20.40)         0.764
                                                                                                                       
                                             (ng/L)                                       (ng/L)                        
                                                                                                                       
  Anti-inflammatory                                                                                                     
   IL-4                    3 (100)           1.95 (1.57--7.96)            5 (100)         1.99 (1.69--2.90)            0.882
   IL-5                    1 (33)            39.43                        1 (20)          9.65                         0.317
   IL-10                   3 (100)           11.80 (11.10--69.56)         3 (60)          20.11 (16.02--22.68)         0.513
   IL-13                   1 (33)            11.27                        1 (20)          5.06                         0.317
                                                                                                                       
                                             (ng/L)                                       (ng/L)                        
                                                                                                                       
  Chemokines                                                                                                            
   IL-8                    3 (100)           31.69 (24.45--85.28)         5 (100)         29.76 (22.37--30.79)         0.655
   GRO-*α* ^‡^             2 (67)            204.44 (−1859.94--2268.82)   3 (60)          55.42 (45.11--65.73)         0.306
   MCP-1                   3 (100)           193.91 (123.14--204.59)      5 (100)         88.62 (60.77--192.54)        0.456
   MIP-1~*β*~              3 (100)           234.90 (210.30--292.20)      5 (100)         174.60 (150.00--250.80)      0.297
                                                                                                                       
                                             (ng/L)                                       (ng/L)                        
                                                                                                                       
  Haematopoietic stimuli                                                                                                
   IL-7                    2 (67)            28.14 (17.72--38.57)         3 (60)          10.48 (8.84--12.50)          0.564
   G-CSF                   3 (100)           30.89 (23.21--96.81)         5 (100)         47.27 (41.84--51.46)         0.655
   GM-CSF                  3 (100)           248.80 (191.00--299.30)      4 (80)          132.35 (114.97--151.83)      0.157

Levels of immune compounds were expressed as median and interquartile range (IQR) when data were not normally distributed and as mean and 95% confidence interval (95% CI) when they were. ^\*^Kruskal-Wallis test was used to determine the differences between blood samples along time when data were not normally distributed and one-way ANOVA test when they were. ^†^Concentration was expressed as ng/L of plasma for all the proinflammatory parameters with the exception of calprotectin whose units were mg/L. ^‡^Normally distributed.

[^1]: Academic Editor: Miguel Gueimonde
